Merus (NASDAQ:MRUS – Get Free Report) has been given a consensus recommendation of “Buy” by the twelve research firms that are covering the company, MarketBeat.com reports. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $82.00.
A number of brokerages recently issued reports on MRUS. Needham & Company LLC decreased their target price on shares of Merus from $92.00 to $85.00 and set a “buy” rating for the company in a research report on Monday, August 5th. Canaccord Genuity Group upgraded shares of Merus to a “strong-buy” rating in a research note on Thursday, July 25th. Guggenheim boosted their target price on Merus from $93.00 to $111.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Citigroup increased their price target on Merus from $70.00 to $93.00 and gave the company a “buy” rating in a research note on Wednesday, June 26th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $67.00 price objective on shares of Merus in a research note on Thursday, July 25th.
Check Out Our Latest Research Report on MRUS
Hedge Funds Weigh In On Merus
Merus Trading Up 1.8 %
MRUS opened at $52.69 on Monday. The business’s 50 day moving average is $50.99 and its 200-day moving average is $50.71. The stock has a market cap of $3.09 billion, a PE ratio of -19.02 and a beta of 1.11. Merus has a twelve month low of $19.81 and a twelve month high of $61.61.
Merus (NASDAQ:MRUS – Get Free Report) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.05). Merus had a negative net margin of 476.41% and a negative return on equity of 36.33%. The business had revenue of $7.33 million for the quarter, compared to the consensus estimate of $9.64 million. As a group, analysts forecast that Merus will post -3.27 EPS for the current year.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Recommended Stories
- Five stocks we like better than Merus
- Conference Calls and Individual Investors
- Is Spotify Stock Poised to Soar? Options Traders Think So
- The Most Important Warren Buffett Stock for Investors: His Own
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- The Significance of Brokerage Rankings in Stock Selection
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.